HLA tumor antigen peptides of class I and II for treating mammary/breast carcinomas

ChangeBridge: Patent Grants - Peptides (C07K)

Published March 31st, 2026

Detected March 31st, 2026

Summary

The USPTO granted Patent US12589142B2 to PMCR GmbH covering pharmaceutical compositions comprising HLA-A tumor antigen peptides (4-8 peptides for MHC class I and 2+ for MHC class II) for treating breast carcinomas. The patent includes 4 claims and covers methods for preparing the composition and determining HLA peptides.

View original document View source feed page

What changed

The USPTO granted Patent US12589142B2 to PMCR GmbH (inventors: Wolfgang Schönharting, Sybille Urban) for a pharmaceutical composition containing HLA tumor antigen peptides for treating breast carcinomas. The composition comprises 4-8 HLA-A peptides corresponding to MHC class I complexes and at least 2 tumor antigen peptides for MHC class II complexes, which are tumor-exclusive or tumor-associated. The patent covers treatment or prophylaxis of mammary carcinomas, including locally recurring or metastasizing forms, as well as other malignancies, leukemias, and neoplasms.

This patent grant establishes intellectual property protection for the technology; no compliance actions are required. Parties interested in licensing or developing similar peptide-based cancer immunotherapies should review this patent for freedom-to-operate considerations. The filing date was June 2, 2020, with application number 17615595.

Source document (simplified)

← USPTO Patent Grants

HLA tumor antigen peptides of class I and II for treating mammary/breast carcinomas

Grant US12589142B2 Kind: B2 Mar 31, 2026

Assignee

PMCR GMBH

Inventors

Wolfgang Schönharting, Sybille Urban

Abstract

The present invention relates to a pharmaceutical composition for use in the treatment or prophylaxis of mammary/breast carcinomas, in particular locally recurring or metastasizing mammary carcinomas in a patient or group of patients, who has or is suspected of having a breast carcinoma, comprising at least 4 to 8 HLA-A tumor antigen peptides corresponding to MHC class I complexes and at least 2 tumor antigen peptides corresponding to MHC class II complexes, wherein the HLA tumor antigen peptides are tumor-exclusive or tumor-associated HLA antigen peptides and are directed against at least one MHC complex including combinations thereof; a pharmaceutical composition, a kit (or parts thereof); a method for determining an HLA peptide of class I and/or II; a method for preparing a pharmaceutical composition according to the invention; and the use of a pharmaceutical composition according to the invention for the preparation of a pharmaceutical composition for the treatment of malignancies, leukemias and neoplasms.